SG11201901941YA - High purity rna compositions and methods for preparation thereof - Google Patents
High purity rna compositions and methods for preparation thereofInfo
- Publication number
- SG11201901941YA SG11201901941YA SG11201901941YA SG11201901941YA SG11201901941YA SG 11201901941Y A SG11201901941Y A SG 11201901941YA SG 11201901941Y A SG11201901941Y A SG 11201901941YA SG 11201901941Y A SG11201901941Y A SG 11201901941YA SG 11201901941Y A SG11201901941Y A SG 11201901941YA
- Authority
- SG
- Singapore
- Prior art keywords
- ppp
- international
- street
- rna
- rna compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 8
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 108020004414 DNA Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111111 111111111 01111 Organization International Bureau (43) International Publication Date . . .., . .. (10) International Publication Number WO 2018/053209 Al 22 March 2018 (22.03.2018) WIP0 I PCT (51) International Patent Classification: MA 02451 (US). BUTORA, Gabor; 200 Technology Cl 2N 15/10 (2006.01) Square, Cambridge, MA 02139 (US). (21) International Application Number: (74) Agent: LOCKHART, Helen C.; Wolf, Greenfield & PCT/US2017/051674 Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (22) International Filing Date: (US). 14 September 2017 (14.09.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/394,711 14 September 2016 (14.09.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: MODERNATX, INC. [US/US]; 320 Bent MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Street, Cambridge, MA 02141 (US). OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors: HOGE, Stephen; 320 Bent Street, Cambridge, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. MA 02141 (US). ISSA, William; 95 Kimball Road, Ded- ham, MA 02026 (US). MIRACCO, Edward J.; 6 Frost (84) Designated States (unless otherwise indicated, for every Street, Arlington, MA 02474 (US). NELSON, Jennifer; kind of regional protection available): ARIPO (BW, GH, — 465 Washington Street, #2, Brookline, MA 02246 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, RABIDEAU, Amy, E.; 121 Pond Street, Unit 1, Waltham, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = (54) Title: HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF = = Figure 40 = = = = DNA plasmid = NTPs = = Linearized dsDNA template 2+ = Mg — = = = 5 'PPP - ,-- -\",, .........vappp 5' = 5 '13PP 5 'PPP -A ino NN... 3' Full-length product Run-on transcripts Reverse Abortive/ truncated transcripts 1 complement ,.._ impurities , = 1€ 5'PPP ;€€€€€€€ 5 'P P :.1 5'PPP EM 113 A ioo N N... 3' wituunsww-ppp 5' samonsitutu-ppp 5' Ennwansmeam-ppp 5' meWmammtata-ppp 5' ireamfamaros-PPP 5' CD . IMIH liJilli © ei PP P 5' Kw:mamma-pp p 5' M 0 i n (57) : The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are ---- particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by inproved *1: processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and 1-1 © purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof. ei O [Continued on next page] WO 2018/053209 Al MIDEDIMOMOIDEIREEMONIMEINEMECIONVOIS TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394711P | 2016-09-14 | 2016-09-14 | |
| PCT/US2017/051674 WO2018053209A1 (en) | 2016-09-14 | 2017-09-14 | High purity rna compositions and methods for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901941YA true SG11201901941YA (en) | 2019-04-29 |
Family
ID=60043282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901941YA SG11201901941YA (en) | 2016-09-14 | 2017-09-14 | High purity rna compositions and methods for preparation thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11202793B2 (en) |
| EP (2) | EP3512944B1 (en) |
| JP (2) | JP6983455B2 (en) |
| CN (2) | CN109937253B (en) |
| AU (2) | AU2017326423B2 (en) |
| CA (1) | CA3036831A1 (en) |
| ES (1) | ES2928475T3 (en) |
| MA (1) | MA46240A (en) |
| MX (1) | MX2019002904A (en) |
| SG (1) | SG11201901941YA (en) |
| WO (1) | WO2018053209A1 (en) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498588A (en) | 1994-09-09 | 1996-03-12 | The Standard Oil Company | Surface modification and promotion of vanadium antimony oxide catalysts |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2015249553B2 (en) | 2014-04-23 | 2021-03-04 | Modernatx, Inc. | Nucleic acid vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
| EP3364983A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Respiratory virus vaccines |
| EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| MA45052A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | POLYNUCLEOTIDES CODING FOR JAGGED1 FOR THE TREATMENT OF ALAGILLUS SYNDROME |
| CN109640962B (en) | 2016-05-18 | 2022-07-19 | 摩登纳特斯有限公司 | Polynucleotides encoding relaxin |
| MX2019002904A (en) | 2016-09-14 | 2019-09-26 | Modernatx Inc | High purity rna compositions and methods for preparation thereof. |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (en) | 2016-12-08 | 2020-08-19 | Modernatx Inc | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| MA47515A (en) | 2017-02-16 | 2019-12-25 | Modernatx Inc | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| EP3609534A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| CN111212905A (en) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | RNA polymerase variants |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| MX2020002348A (en) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Methods of making lipid nanoparticles. |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| CN113271926A (en) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | Preparation of lipid nanoparticles and methods of administration thereof |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN113795579A (en) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | RNA polymerase variants for co-transcriptional capping |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| US20220145381A1 (en) * | 2019-03-11 | 2022-05-12 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| EP4010350A4 (en) | 2019-08-09 | 2023-11-22 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
| CN110812366B (en) * | 2019-11-18 | 2023-11-17 | 珠海丽凡达生物技术有限公司 | mRNA medicine for hormone supplement and preparation method thereof |
| AU2021213108A1 (en) | 2020-01-28 | 2022-08-18 | Modernatx, Inc. | Coronavirus RNA vaccines |
| US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
| IL295377A (en) | 2020-02-07 | 2022-10-01 | Modernatx Inc | Sars-cov-2 mrna domain vaccines |
| GB2594364A (en) | 2020-04-22 | 2021-10-27 | Biontech Rna Pharmaceuticals Gmbh | Coronavirus vaccine |
| WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
| WO2021231963A1 (en) * | 2020-05-15 | 2021-11-18 | Modernatx, Inc. | Rna formulations for high volume distribution, and methods of using the same for treating covid-19 |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20230355743A1 (en) | 2020-09-25 | 2023-11-09 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| WO2022082001A1 (en) * | 2020-10-15 | 2022-04-21 | Translate Bio, Inc. | Large scale synthesis of messenger rna |
| KR20230164648A (en) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | RNA vaccines against SARS-CoV-2 variants |
| US20230000970A1 (en) | 2021-01-11 | 2023-01-05 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| EP4277653A1 (en) | 2021-01-15 | 2023-11-22 | ModernaTX, Inc. | Variant strain-based coronavirus vaccines |
| WO2022155524A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| JP2024511346A (en) | 2021-03-15 | 2024-03-13 | モデルナティエックス インコーポレイテッド | Therapeutic use of SARS-COV-2 mRNA domain vaccines |
| WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
| BR112023023760A2 (en) * | 2021-05-26 | 2024-01-30 | Etherna Immunotherapies Nv | METHOD TO REDUCE THE FORMATION OF DOUBLE-STANNED RNA BYPRODUCT |
| CN117730149A (en) * | 2021-06-14 | 2024-03-19 | 2赛文缇生物公司 | Single-stranded RNA purification method |
| US20240218353A1 (en) | 2021-06-17 | 2024-07-04 | Modernatx, Inc. | Alternative rna purification strategies |
| WO2023031773A1 (en) * | 2021-08-31 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Ivt rna manufacturing process |
| CA3235867A1 (en) | 2021-10-22 | 2023-04-27 | Munir MOSAHEB | Mrna vaccine composition |
| WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| CN118488834A (en) | 2021-11-23 | 2024-08-13 | 赛欧生物医药股份有限公司 | Bacterial-derived lipid composition and use thereof |
| WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
| WO2023112886A1 (en) * | 2021-12-16 | 2023-06-22 | 国立研究開発法人理化学研究所 | Method for producing single-stranded rna |
| WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
| WO2023137149A1 (en) * | 2022-01-14 | 2023-07-20 | Modernatx, Inc. | In vitro transcription dna purification and recycling |
| WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024015890A1 (en) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
| WO2024020194A1 (en) * | 2022-07-22 | 2024-01-25 | Modernatx, Inc. | Compositions and methods for detecting dsrna |
| WO2024050483A1 (en) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
| WO2024055941A1 (en) * | 2022-09-13 | 2024-03-21 | Suzhou Abogen Biosciences Co., Ltd. | One-step method for synthesis of circular rna |
| WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
| WO2024153794A1 (en) | 2023-01-20 | 2024-07-25 | Astrazeneca Ab | Vaccine |
| WO2024153793A1 (en) | 2023-01-20 | 2024-07-25 | Astrazeneca Ab | Nucleic acid molecules |
| WO2024159172A1 (en) | 2023-01-27 | 2024-08-02 | Senda Biosciences, Inc. | A modified lipid composition and uses thereof |
| WO2024163465A1 (en) | 2023-01-30 | 2024-08-08 | Modernatx, Inc. | Epstein-barr virus mrna vaccines |
| WO2024191860A2 (en) | 2023-03-10 | 2024-09-19 | Modernatx, Inc. | Nucleic acid influenza vaccines and respiratory virus combination vaccines |
| WO2024206835A1 (en) | 2023-03-30 | 2024-10-03 | Modernatx, Inc. | Circular mrna and production thereof |
| WO2024215721A1 (en) | 2023-04-10 | 2024-10-17 | Modernatx, Inc. | Lyme disease vaccines |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| CN116606867B (en) * | 2023-04-28 | 2024-01-26 | 北京启辰生生物科技有限公司 | Preparation method and application for improving mRNA integrity of novel crown full-length S protein |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100024A (en) | 1991-02-08 | 2000-08-08 | Promega Corporation | Methods and compositions for nucleic acid detection by target extension and probe amplification |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US6096503A (en) | 1993-11-12 | 2000-08-01 | The Scripps Research Institute | Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations |
| FR2733762B1 (en) | 1995-05-02 | 1997-08-01 | Genset Sa | METHOD FOR THE SPECIFIC COUPLING OF THE HAIR OF THE 5 'END OF A RNAM FRAGMENT AND PREPARATION OF RNAM AND COMPLETE DNA |
| US6251665B1 (en) | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
| WO2001025488A2 (en) | 1999-10-06 | 2001-04-12 | Quark Biotech, Inc. | Method for enrichment of natural antisense messenger rna |
| US20030165849A1 (en) * | 2000-11-28 | 2003-09-04 | Biliang Zhang | Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA |
| AU2002230997A1 (en) * | 2000-12-15 | 2002-06-24 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
| US8426194B2 (en) | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
| GB0316089D0 (en) | 2003-07-09 | 2003-08-13 | Xo Bioscience Ltd | Differentiation method |
| EP2311994A1 (en) * | 2003-08-01 | 2011-04-20 | Life Technologies Corporation | Compositions and methods for preparing short RNA molecules and other nucleic acids |
| US20140142290A1 (en) | 2003-08-01 | 2014-05-22 | Life Technologies Corporation | Compositions and methods for preparing short rna molecules and other nucleicacids |
| US20050287539A1 (en) * | 2004-06-29 | 2005-12-29 | Emmanuel Labourier | Methods and compositions for preparing capped RNA |
| US20080220471A1 (en) | 2005-07-27 | 2008-09-11 | Genentech, Inc. | Vectors and Methods Using Same |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| SI3611266T1 (en) | 2005-08-23 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| CA2649325C (en) | 2006-04-14 | 2019-01-08 | Epicentre Technologies Corporation | Kits and methods for generating 5' capped rna |
| DK2104739T3 (en) | 2006-12-21 | 2013-10-07 | Novozymes Inc | Modified messenger RNA stabilization sequences for expression of genes in bacterial cells |
| DE102006061015A1 (en) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Process for the purification of RNA on a preparative scale by HPLC |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| US8808982B2 (en) | 2009-12-07 | 2014-08-19 | Cellscript, Llc | Compositions and methods for reprogramming eukaryotic cells |
| EP2575895A2 (en) | 2010-05-24 | 2013-04-10 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| WO2012038450A1 (en) | 2010-09-21 | 2012-03-29 | Riboxx Gmbh | Microwave-driven rna polymerization by rna polymerases of caliciviruses |
| DE19177059T1 (en) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | RIBONUCLEIC ACID CONTAINING N1-METHYL-PSEUDOURACILE AND USES |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012158736A1 (en) | 2011-05-17 | 2012-11-22 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof for non-human vertebrates |
| WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013130161A1 (en) | 2011-12-14 | 2013-09-06 | modeRNA Therapeutics | Methods of responding to a biothreat |
| PL2791160T3 (en) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Modified mrna compositions |
| US20130165504A1 (en) | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
| CA2862377A1 (en) | 2011-12-30 | 2013-07-04 | Cellscript, Llc | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect |
| DE18200782T1 (en) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | Enzymes and polymerases for the synthesis of rna |
| RS63237B1 (en) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminally modified rna |
| EP2931914A4 (en) | 2012-12-13 | 2016-08-17 | Moderna Therapeutics Inc | Modified polynucleotides for altering cell phenotype |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Removal of dna fragments in mrna production process |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| TR201903248T4 (en) | 2013-03-15 | 2019-03-21 | Glaxosmithkline Biologicals Sa | Rna purification methods. |
| US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
| CA2927393A1 (en) | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| AU2015249553B2 (en) | 2014-04-23 | 2021-03-04 | Modernatx, Inc. | Nucleic acid vaccines |
| AU2015273933B2 (en) | 2014-06-10 | 2021-02-11 | CureVac Manufacturing GmbH | Methods and means for enhancing RNA production |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| CA2955375A1 (en) | 2014-07-17 | 2016-01-21 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| EP3247363A4 (en) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| WO2016201377A1 (en) | 2015-06-10 | 2016-12-15 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| WO2017015457A1 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
| WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
| WO2017019935A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Multimeric mrna |
| MA42543A (en) | 2015-07-30 | 2018-06-06 | Modernatx Inc | CONCATEMERIC PEPTIDIC EPITOPE RNA |
| US20180237849A1 (en) | 2015-08-17 | 2018-08-23 | Modernatx, Inc. | Rna mapping/fingerprinting |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| HUE057613T2 (en) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| KR20180096591A (en) | 2015-10-22 | 2018-08-29 | 모더나티엑스, 인크. | A broad-spectrum influenza virus vaccine |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| US20180318409A1 (en) | 2015-10-22 | 2018-11-08 | Modernatx, Inc. | Cancer vaccines |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20180303929A1 (en) | 2015-10-22 | 2018-10-25 | Moderna TX, Inc. | Herpes simplex virus vaccine |
| JP2019501208A (en) | 2015-10-22 | 2019-01-17 | モデルナティーエックス， インコーポレイテッド | Respiratory syncytial virus vaccine |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
| EP3364983A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Respiratory virus vaccines |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
| EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
| MA43568A (en) | 2015-12-17 | 2018-11-14 | Modernatx Inc | POLYNUCLEOTIDES CODING FOR METHYLMALONYL-COA MUTASE |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3458108A4 (en) | 2016-05-18 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP3896164A1 (en) | 2016-05-18 | 2021-10-20 | ModernaTX, Inc. | Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease |
| JP2019519516A (en) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | MRNA combination therapy for the treatment of cancer |
| WO2017201317A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| MA45050A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | LIPOPROTEIN LIPASE CODING POLYNUCLEOTIDES FOR THE TREATMENT OF HYPERLIPIDEMIA |
| WO2017201349A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
| CN109640962B (en) | 2016-05-18 | 2022-07-19 | 摩登纳特斯有限公司 | Polynucleotides encoding relaxin |
| MA45052A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | POLYNUCLEOTIDES CODING FOR JAGGED1 FOR THE TREATMENT OF ALAGILLUS SYNDROME |
| MA45032A (en) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | POLYNUCLEOTIDES CODING FOR PORPHOBILINOGEN DESAMINASE FOR THE TREATMENT OF ACUTE INTERMITTEN PORPHYRIA |
| WO2017201348A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| CA3027201A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MX2019002904A (en) * | 2016-09-14 | 2019-09-26 | Modernatx Inc | High purity rna compositions and methods for preparation thereof. |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| EP3532613A4 (en) | 2016-10-26 | 2020-05-06 | ModernaTX, Inc. | Methods and compositions for rna mapping |
| SG11201903674YA (en) | 2016-10-26 | 2019-05-30 | Modernatx Inc | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (en) | 2016-12-08 | 2020-08-19 | Modernatx Inc | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| US20180243225A1 (en) | 2017-01-25 | 2018-08-30 | Modernatx, Inc. | Ebola/marburg vaccines |
| KR20190110612A (en) | 2017-02-01 | 2019-09-30 | 모더나티엑스, 인크. | Immunomodulatory Therapeutic MRNA Compositions Encoding Activating Oncogene Mutant Peptides |
| NZ755780A (en) | 2017-02-01 | 2023-10-27 | Modernatx Inc | Rna cancer vaccines |
| WO2018144778A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Polynucleotide secondary structure |
| MA47515A (en) | 2017-02-16 | 2019-12-25 | Modernatx Inc | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US20200368162A1 (en) | 2017-02-24 | 2020-11-26 | Modernatx, Inc. | Nucleic Acid-Based Therapy of Muscular Dystrophies |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| EP3609534A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| HRP20230063T1 (en) | 2017-03-15 | 2023-03-17 | Modernatx, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| WO2018175783A1 (en) | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US20200054737A1 (en) | 2017-04-26 | 2020-02-20 | Modema TX, Inc. | Herpes simplex virus vaccine |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2018232355A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna antibodies |
| US20200254086A1 (en) | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| CN111212905A (en) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | RNA polymerase variants |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| US20190192646A1 (en) | 2017-11-03 | 2019-06-27 | Modernatx, Inc. | Salmonella vaccines |
| EP3713601A4 (en) | 2017-11-21 | 2022-03-09 | Modernatx, Inc. | Epstein-barr virus vaccines |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| SG11202012770RA (en) | 2018-06-27 | 2021-01-28 | Modernatx Inc | Personalized cancer vaccine epitope selection |
| WO2020056370A1 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders |
| US20220409536A1 (en) | 2018-09-19 | 2022-12-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3853305B1 (en) | 2018-09-19 | 2024-10-02 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (en) | 2018-09-19 | 2021-07-28 | Modernatx Inc | PEG LIPIDS AND THEIR USES |
| MA54192A (en) | 2018-11-07 | 2021-09-15 | Modernatx Inc | RNA VACCINES AGAINST CANCER |
| CN113795579A (en) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | RNA polymerase variants for co-transcriptional capping |
| US20220145381A1 (en) | 2019-03-11 | 2022-05-12 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| MA56060A (en) | 2019-05-31 | 2022-04-06 | Modernatx Inc | EXPANDED T LYMPHOCYTE ASSAY |
| EP4013865A4 (en) | 2019-08-14 | 2023-08-23 | ModernaTX, Inc. | Processes for purifying downstream products of in vitro transcription |
| WO2021050864A1 (en) | 2019-09-11 | 2021-03-18 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4031666A4 (en) | 2019-09-19 | 2023-11-15 | ModernaTX, Inc. | Cap guides and methods of use thereof for rna mapping |
| WO2021142306A1 (en) | 2020-01-10 | 2021-07-15 | Modernatx, Inc. | Variational autoencoder for biological sequence generation |
| US20210228707A1 (en) | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| CA3169664A1 (en) | 2020-01-30 | 2021-08-05 | Modernatx, Inc. | Respiratory virus immunizing compositions |
| IL295377A (en) | 2020-02-07 | 2022-10-01 | Modernatx Inc | Sars-cov-2 mrna domain vaccines |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
-
2017
- 2017-09-14 MX MX2019002904A patent/MX2019002904A/en unknown
- 2017-09-14 CN CN201780069684.2A patent/CN109937253B/en active Active
- 2017-09-14 MA MA046240A patent/MA46240A/en unknown
- 2017-09-14 EP EP17781233.6A patent/EP3512944B1/en active Active
- 2017-09-14 SG SG11201901941YA patent/SG11201901941YA/en unknown
- 2017-09-14 US US16/333,330 patent/US11202793B2/en active Active
- 2017-09-14 EP EP22182206.7A patent/EP4166666A1/en active Pending
- 2017-09-14 WO PCT/US2017/051674 patent/WO2018053209A1/en unknown
- 2017-09-14 CN CN202310687777.9A patent/CN116837052A/en active Pending
- 2017-09-14 CA CA3036831A patent/CA3036831A1/en active Pending
- 2017-09-14 AU AU2017326423A patent/AU2017326423B2/en active Active
- 2017-09-14 JP JP2019535224A patent/JP6983455B2/en active Active
- 2017-09-14 ES ES17781233T patent/ES2928475T3/en active Active
-
2018
- 2018-06-06 US US16/001,786 patent/US10653712B2/en active Active
-
2021
- 2021-09-24 JP JP2021155734A patent/JP7566710B2/en active Active
- 2021-11-10 US US17/523,060 patent/US20220096522A1/en active Pending
- 2021-11-10 US US17/523,034 patent/US20220096521A1/en active Pending
-
2024
- 2024-02-09 AU AU2024200861A patent/AU2024200861A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180363019A1 (en) | 2018-12-20 |
| JP2022000458A (en) | 2022-01-04 |
| US11202793B2 (en) | 2021-12-21 |
| MX2019002904A (en) | 2019-09-26 |
| US20220096521A1 (en) | 2022-03-31 |
| AU2017326423B2 (en) | 2023-11-09 |
| EP4166666A1 (en) | 2023-04-19 |
| US20190247417A1 (en) | 2019-08-15 |
| CN109937253B (en) | 2023-06-30 |
| AU2024200861A1 (en) | 2024-02-29 |
| US10653712B2 (en) | 2020-05-19 |
| JP7566710B2 (en) | 2024-10-15 |
| MA46240A (en) | 2019-07-24 |
| JP2019533476A (en) | 2019-11-21 |
| JP6983455B2 (en) | 2021-12-17 |
| US20220096522A1 (en) | 2022-03-31 |
| EP3512944B1 (en) | 2022-07-06 |
| WO2018053209A1 (en) | 2018-03-22 |
| CN116837052A (en) | 2023-10-03 |
| CA3036831A1 (en) | 2018-03-22 |
| AU2017326423A1 (en) | 2019-03-28 |
| EP3512944A1 (en) | 2019-07-24 |
| CN109937253A (en) | 2019-06-25 |
| ES2928475T3 (en) | 2022-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901941YA (en) | High purity rna compositions and methods for preparation thereof | |
| SG11201810210UA (en) | Engineered botulinum neurotoxins | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201809522WA (en) | Method of nucleic acid sequence determination | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201901563UA (en) | De novo synthesized nucleic acid libraries | |
| SG11201808721YA (en) | Cell-free production of ribonucleic acid | |
| SG11201810286WA (en) | Variable diameter bioreactors | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201806284TA (en) | Low pressure separator having an internal divider and uses therefor | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804884PA (en) | Method for modulating autophagy and applications thereof | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts |